Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CHEK2 variants associate with hereditary prostate cancer.

E H Seppälä1, T Ikonen, N Mononen

  • 1Laboratory of Cancer Genetics, Institute of Medical Technology, Lenkkeilijänkatu 8,University of Tampere and Tampere University Hospital, FIN-33014 University of Tampere, Finland.

British Journal of Cancer
|November 13, 2003
PubMed
Summary

Genetic variants in the CHEK2 gene are linked to hereditary prostate cancer (HPC). This study found specific CHEK2 mutations, 1100delC and I157T, were more common in Finnish HPC patients, suggesting a role in familial prostate cancer risk.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Statin use and outcomes of oncological treatment for castration-resistant prostate cancer.

Scientific reports·2023
Same author

Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse.

Nature communications·2021
Same author

Outcomes of prostate cancer screening among men using antidiabetic medication.

Scientific reports·2021
Same author

Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study.

Prostate cancer and prostatic diseases·2021
Same author

Anticoagulants and cancer mortality in the Finnish randomized study of screening for prostate cancer.

Cancer causes & control : CCC·2019
Same author

The rs2516839 variation of USF1 gene is associated with 4-year mortality of nonagenarian women: The Vitality 90+ study.

Annals of human genetics·2018

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • CHEK2 gene variants have been associated with sporadic prostate cancer.
  • Understanding genetic predispositions for hereditary prostate cancer (HPC) is crucial for risk assessment and prevention.

Purpose of the Study:

  • To investigate the association of specific CHEK2 variants (1100delC and I157T) with hereditary prostate cancer in a Finnish cohort.
  • To determine if these CHEK2 variants contribute to the familial clustering of prostate cancer.

Main Methods:

  • Case-control study comparing allele frequencies in 120 HPC patients and 480 population controls from Finland.
  • Genotyping for the CHEK2 1100delC and I157T variants.
  • Segregation analysis within families with a history of prostate cancer.

Related Experiment Videos

Main Results:

  • The truncating CHEK2 variant 1100delC was significantly elevated in HPC patients (3.3%) compared to controls (OR=8.24, P=0.02).
  • Suggestive evidence of segregation of the 1100delC mutation with prostate cancer was observed in affected families.
  • The CHEK2 I157T variant was also more frequent in HPC patients (10.8%) than in controls (OR=2.12, P=0.04).

Conclusions:

  • CHEK2 variants, including 1100delC and I157T, appear to be low-penetrance alleles predisposing to prostate cancer.
  • These variants may contribute to the familial aggregation of prostate cancer within the population.